Driving Laws and Prescribed Cannabis: Northern Territory

The NT has a zero-tolerance drug driving law , and prescriptions don't change that

Roughly 400,000 Australians now hold a valid prescription for medicinal cannabis. The Northern Territory is no exception to that growth curve. But a question I keep seeing in regulatory forums and community groups hasn't been answered clearly in one place: if you're a lawfully prescribed patient in the NT, what does that mean , legally , the moment you get behind the wheel?

The short version is uncomfortable but important: it means very little, at least as the law currently stands.

The NT's Traffic Act 1987 (Cth/NT) and the framework under the Transport (Compliance and Miscellaneous) Act 1994 together give police the power to test drivers for the presence of prescribed illicit substances; which includes tetrahydrocannabinol (THC), the primary psychoactive cannabinoid in cannabis. Roadside drug testing in the NT uses oral fluid swabs that detect THC. The legal standard is presence, not impairment. There is no concentration threshold above which you fail and below which you pass. If the swab detects THC, you have committed an offence.

A lawful prescription under the TGA's access framework does not provide a statutory defence to that offence under current NT law. That's the part most people don't hear clearly enough.

How prescribed cannabis access actually works in Australia

To understand why the driving law creates such a bind, it helps to understand what "prescribed cannabis" means under the federal framework. Medicinal cannabis products in Australia are accessed through one of two primary TGA pathways: the Special Access Scheme (usually Category B, for individual patients), or via an Authorised Prescriber, a clinician approved by the TGA to prescribe specific products to a class of patients without needing per-patient SAS approval.

Products may appear on the Australian Register of Therapeutic Goods (ARTG), or they may be unapproved products accessed via SAS-B. Most prescribed cannabis products in Australia currently fall into the unapproved-but-legally-accessed category. Depending on cannabinoid profile, they sit as either Schedule 4 (Prescription Only) medicines, generally for products where cannabidiol (CBD) predominates; or Schedule 8 (Controlled Drug), which applies to products containing meaningful concentrations of THC.

Schedule 8 classification exists because THC has recognised potential for dependence and misuse, and because, here's where driving becomes relevant, it is detectable in oral fluid for a variable period after use. That window isn't fixed. It depends on the product's formulation, whether it's full-spectrum or otherwise, how often the patient uses it, and individual pharmacokinetics. Some people test clear within hours; others carry detectable levels for much longer. There's no reliable personal predictor, which makes the driving question genuinely difficult for patients to manage.

What NT law says specifically

Under the NT's drug driving provisions, it is an offence to drive, or be in control of, a motor vehicle while a prescribed illicit drug is present in your oral fluid, blood, or urine. THC is a prescribed illicit drug for these purposes. The test is presence-based; not impairment-based. This approach aligns broadly with most Australian jurisdictions, though implementation details vary.

Critically, the NT legislation does not include a medical exemption or prescription defence equivalent. Some other jurisdictions have begun to explore frameworks that might allow for such a defence, but as of the time of writing, the NT has not legislated one. The NT Police and the Department of Infrastructure, Planning and Logistics administer transport compliance, and their published guidance is consistent: a valid prescription is not a defence to a positive roadside drug test result.

Penalties in the NT for a first drug driving offence can include fines, licence disqualification, and, in some circumstances; the possibility of a recorded conviction. Repeat or aggravated offences carry escalating consequences. These are set out in the Traffic Act 1987 and associated regulations, and I'd strongly encourage anyone affected to read the current NT legislation directly or take independent legal advice, because penalty scales and procedural requirements do get updated.

The impairment gap: where science and law diverge

Here's where I'll admit I find the policy framework genuinely frustrating, not because I think impaired driving should be excused, but because presence-based testing doesn't measure impairment. It measures recent exposure, and the two are not the same thing.

THC interacts primarily with CB1 receptors in the central nervous system, including brain regions that govern coordination and reaction time. Acute impairment following cannabis use is real and well-documented in the research literature. But oral fluid THC detection windows extend well beyond the window of impairment for many users, particularly those who use prescribed products regularly. A patient who last dosed the evening before may return a positive swab while showing no functional impairment whatsoever. The roadside test cannot distinguish between these scenarios.

Several Australian jurisdictions have commissioned or participated in research on this gap, and it's an active policy debate nationally. The Therapeutic Goods Administration is a federal body and doesn't set road rules, that sits with states and territories; so there's a structural tension baked into the system that isn't easily resolved at the federal level.

In my view, the lag between federal legitimisation of prescribed cannabis and state/territory driving law reform is the single most significant unresolved practical barrier for patients in Australia right now. That's not a radical position; it's one shared quietly by a fair number of people in the access policy space.

What patients and prescribers should know

If you are a patient prescribed a cannabis product containing THC, particularly a Schedule 8 product, in the Northern Territory, the practical reality is this:

• You are at legal risk if you drive and return a positive oral fluid result, regardless of your prescription status.
• The detection window for THC in oral fluid is variable and not reliably predictable at an individual level.
• There is no current NT statutory defence tied to holding a lawful prescription.
• Your prescribing doctor should be discussing driving implications with you as part of informed consent; if they haven't, it's worth raising directly.

For products where CBD predominates and THC is absent or at trace levels (think a Schedule 4 CBD isolate or broad-spectrum product processed to remove THC), the roadside oral fluid test, which targets THC, not CBD, would not be expected to return a positive result for THC. But this depends entirely on the actual formulation of the product you've been prescribed. Don't assume. Ask your pharmacist or prescriber for written clarification on the cannabinoid profile of your specific medicine.

I was talking to a colleague in Darwin last year; she'd been watching the TGA's access data closely, and she made the point that the volume of NT prescriptions had grown significantly, but the public information available to NT patients about driving implications was patchy at best. That assessment still holds, honestly.

Checking current law, don't rely solely on this article

Laws change. NT transport legislation is subject to amendment, and there's ongoing national discussion about whether prescription defences should be introduced across jurisdictions. The NT Department of Infrastructure, Planning and Logistics and NT Police publish current guidance. The TGA's website covers the federal access framework. Always verify the current version of the Traffic Act 1987 (NT) and associated regulations through the NT legislation register, and take independent legal advice if you're uncertain about your specific situation.

Staying across Trevor (my sourdough starter, not a lawyer) is much easier than staying across NT transport law; he just needs feeding twice a week. Road rules for prescribed cannabis patients need more active attention than that.

Sources

• Medicinal Cannabis: Information for Patients, Therapeutic Goods Administration (TGA)
• Traffic Act 1987, NT Legislation Register
• Cannabis Drug Facts; Alcohol and Drug Foundation (ADF)
• Oral Fluid Drug Testing and Driving Impairment, National Library of Medicine (NCBI)

, Marcus Hale, Regulatory researcher, TGA & access law